Skip to content
Home/Companies/Biotech/Aprea Therapeutics
AT

Aprea Therapeutics

Biotech·Sweden·Exited 2019·Held 6yr

Aprea Therapeutics is a biotech company, headquartered in Sweden.

Entry
2013
Hold
6yr
Exit
2019
Est. EV
–

Who owns Aprea Therapeutics?

Aprea Therapeutics was owned by Rosetta Capital through Rosetta Capital IV (2013 vintage) from 2013 to 2019, exited via IPO.

Hand-verified · updated 2026-06-30

Rosetta Capital
Investor
Rosetta Capital
Rosetta Capital IV · 2013 · Secondaries

Key facts

HQSweden
SectorBiotech
StatusAcquired
Exit Type
IPO
Buyer
–
MOIC
–
Exit Year
2019

More from Rosetta Capital IV

Other portfolio companies in the same fund.

Akinion Pharmaceuticals
Active
PharmaSweden· 2013
Axelar
Active
BiotechSweden· 2013
Biosergen
Exited 2021
BiotechSweden· 2013
Clanotech
Active
BiotechSweden· 2013
Dilafor
Active
BiotechSweden· 2013
Inhalation Sciences
Active
MedTechSweden· 2013

More PE-backed in Biotech

Comparable biotech deals from other GPs.

GenSight Biologics
Active
Sofinnova PartnersFrance
InBrain Pharma
Active
Finovam GestionFrance
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
Univercells
Exited 2023
AdBio PartnersBelgium
to
Data refreshed weekly · Sourced from public filings